Nuvation Bio Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Nuvation Bio Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $3.50M, a 359.58% increase year-over-year.
- Nuvation Bio Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $908.00K, a 16.08% decline year-over-year.
- Nuvation Bio Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $558.00K, a 66.59% decline year-over-year.
- Nuvation Bio Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $762.00K, a 60.88% decline year-over-year.
- Nuvation Bio Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $10.11M, a 126.81% increase from fiscal 2024.
- Nuvation Bio Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $4.46M, a 1088.80% increase from fiscal 2023.
- Nuvation Bio Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $375.00K, a 60.06% decline from fiscal 2022.
- Nuvation Bio Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $939.00K, a 108.67% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $3.50M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $908.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $10.11M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $558.00K 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $762.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $1.08M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $4.46M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $1.67M 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $1.95M 10-Q · filed 2025-11-03 | |
| 2024-03-31 | $21.00K 10-Q · filed 2025-11-03 | |
| 2023-12-31 | $375.00K 10-K · filed 2025-03-06 | |
| 2023-09-30 | $77.00K 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $298.00K 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $939.00K 10-K · filed 2024-02-29 | |
| 2022-09-30 | $258.00K 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $56.00K 10-Q · filed 2023-11-02 | |
| 2022-03-31 | $314.00K 10-Q · filed 2023-11-02 | |
| 2021-12-31 | $450.00K 10-K · filed 2023-03-15 | |
| 2021-09-30 | $30.00K 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $190.00K 10-Q · filed 2022-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |